New Launch23 Dec 2025, 08:52 am
Glenmark Pharmaceuticals Inc., USA Launches Epinephrine Injection USP, 30 mg/30 mL Multiple-Dose Vial
AI Summary
Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029. The Epinephrine Injection USP market achieved annual sales of approximately $67.6 million as per IQVIA™ sales data for the 12-month period ending October 2025. Glenmark's product is only approved for the indications listed in Glenmark’s approved label.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial.
- The product is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029.
- The Epinephrine Injection USP market achieved annual sales of approximately $67.6 million as per IQVIA™ sales data for the 12-month period ending October 2025.
- Glenmark’s product is only approved for the indications listed in Glenmark’s approved label.
- The launch strengthens Glenmark’s commitment to bring to market quality and affordable alternatives for patients.